NICE Medtech Innovation Briefing Supports HemaClear Tourniquet for Bloodless Surgical Field

NICE MIB Supports HemaClear Tourniquet for Bloodless Surgical Field During Limb Surgery

[Click the link above for the full referenced NICE MIB article]

Medtech innovation briefing [MIB187] Published date: 

operating theatres and anaesthesia products hemaclear exsanguination tourniquet range


We are pleased to announce that the NICE Medtech Innovation Briefing has been completed and published in July in support of our unique all-in-one HemaClear Tourniquet Range for orthopaedic procedures in the surgical environment:

  • Bloodless, dry surgical field – avoids risks of incomplete exsanguination
  • Reduced incidence of post-op DVT and pulmonary embolism
  • 15 second patient setup time with HemaClear® application – Time saving vs traditional methods

The Inefficiencies With Traditional Methods 

  • Time wasted: Traditional methods require 12 minutes of patient setup time vs. 15 seconds with HemaClear® application
  • Inefficiency and aggregate cost of multiple products used during a procedure that employs the pneumatic tourniquet vs. the single-use sterile HemaClear® device.
  • OR clutter and shelf space incurred by the pneumatic tourniquet method is eliminated by HemaClear®.

Key features:

  • Bloodless, dry surgical field – avoids risks of incomplete exsanguination
  • Improved anatomical visibility
  • Reduced incidence of post-op DVT
  • Reduced incidence of pulmonary embolism
  • Reduces blood loss, resulting in decreased need for blood transfusion

If you would like further information on our HemaClear tourniquet range, or would like to request a representative meeting, please complete the form below:

Request a Meeting

  • This field is for validation purposes and should be left unchanged.